This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00390455
First received: October 18, 2006
Last updated: June 23, 2017
Last verified: June 2017
Results First Received: June 1, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Estrogen Receptor Positive
HER2 Positive Breast Carcinoma
HER2/Neu Negative
Progesterone Receptor Positive
Recurrent Breast Carcinoma
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
Interventions: Drug: Fulvestrant
Other: Laboratory Biomarker Analysis
Drug: Lapatinib Ditosylate
Other: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Between September 2006 and July 2010, 295 participants were recruited.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Arm I (Lapatinib) Patients receive 1500 mg lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg)of each subsequent course.
Arm II (Placebo) Patients receive placebo PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg) of each subsequent course.

Participant Flow:   Overall Study
    Arm I (Lapatinib)   Arm II (Placebo)
STARTED   148   147 
COMPLETED   116   124 
NOT COMPLETED   32   23 
Adverse Event                17                3 
Withdrawal by Subject                8                8 
Alternate Treatment                0                1 
Other Medical Reasons                7                11 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Four (4) participants who never started treatment were excluded from all analyses

Reporting Groups
  Description
Arm I (Lapatinib) Patients receive 1500 mg lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg)of each subsequent course.
Arm II (Placebo) Patients receive placebo PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg) of each subsequent course.
Total Total of all reporting groups

Baseline Measures
   Arm I (Lapatinib)   Arm II (Placebo)   Total 
Overall Participants Analyzed 
[Units: Participants]
 146   145   291 
Age, Customized 
[Units: Participants]
     
<40   8   7   15 
40-49   21   17   38 
50-59   49   54   103 
60-69   41   47   88 
70+   27   20   47 
Sex: Female, Male 
[Units: Participants]
Count of Participants
     
Female      146 100.0%      145 100.0%      291 100.0% 
Male      0   0.0%      0   0.0%      0   0.0% 
Ethnicity (NIH/OMB) 
[Units: Participants]
Count of Participants
     
Hispanic or Latino      7   4.8%      7   4.8%      14   4.8% 
Not Hispanic or Latino      130  89.0%      129  89.0%      259  89.0% 
Unknown or Not Reported      9   6.2%      9   6.2%      18   6.2% 
Race (NIH/OMB) 
[Units: Participants]
Count of Participants
     
American Indian or Alaska Native      1   0.7%      0   0.0%      1   0.3% 
Asian      4   2.7%      2   1.4%      6   2.1% 
Native Hawaiian or Other Pacific Islander      0   0.0%      0   0.0%      0   0.0% 
Black or African American      11   7.5%      8   5.5%      19   6.5% 
White      127  87.0%      132  91.0%      259  89.0% 
More than one race      0   0.0%      2   1.4%      2   0.7% 
Unknown or Not Reported      3   2.1%      1   0.7%      4   1.4% 
Region of Enrollment 
[Units: Participants]
     
United States   146   145   291 
Prior tamoxifen therapy 
[Units: Participants]
     
Yes   83   82   165 
No   63   63   126 
Bond disease only 
[Units: Participants]
     
Yes   45   43   88 
No   101   102   203 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Progression-free Survival (PFS)   [ Time Frame: Interval from randomization until disease progression or death, whichever occurs first, assessed up to 5 years ]

2.  Secondary:   Objective Tumor Response Rate   [ Time Frame: Up to 5 years ]

3.  Secondary:   Overall Survival (OS)   [ Time Frame: Study entry to death or last follow-up, up to 5 years ]

4.  Other Pre-specified:   Progression-free Survival for Participants With HER2-negative Tumors   [ Time Frame: Up to 5 years ]

5.  Other Pre-specified:   Progression-free Survival for Participants With HER2-positive Tumors   [ Time Frame: Up to 5 years ]

6.  Other Pre-specified:   Objective Tumor Response Rate for Participants With HER2-negative Tumors   [ Time Frame: Up to 5 years ]

7.  Other Pre-specified:   Objective Tumor Response Rate for Participants With HER2-positive Tumors   [ Time Frame: Up to 5 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Harold Burstein, M.D.
Organization: Dana-Farber Cancer Institue
e-mail: hburstein@partners.org


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00390455     History of Changes
Other Study ID Numbers: NCI-2009-00475
NCI-2009-00475 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
CDR0000510452
CALGB-40302 ( Other Identifier: Alliance for Clinical Trials in Oncology )
CALGB-40302 ( Other Identifier: CTEP )
U10CA180821 ( U.S. NIH Grant/Contract )
U10CA031946 ( U.S. NIH Grant/Contract )
Study First Received: October 18, 2006
Results First Received: June 1, 2015
Last Updated: June 23, 2017